Compounds from <em>Terminalia mantaly</em> L. (Combretaceae) Stem Bark Exhibit Potent Inhibition against some Pathogenic Yeasts and Enzymes of Metabolic Significance<strong></strong> by Tchuenmogne, Marthe Aimée Tchuente et al.
Article 
Compounds from Terminalia mantaly L. (Combretaceae) 
Stem Bark Exhibit Potent Inhibition against some 
Pathogenic Yeasts and Enzymes of Metabolic Significance 
 
Marthe Aimée Tchuente Tchuenmogne 1, Thierry Kammalac Ngouana 2,  
Sebastian Gohlke 3, Rufin M. T. Kouipou 2, Abdulselam Aslan 4, Muslum Kuzu 5,  
Veysel Comakli 6, Ramazan Demirdag 6, Silvère A. Ngouela 1, Etienne Tsamo 1,  
Norbert Sewald 3, Bruno N. Lenta 7 and Fabrice F. Boyom 2,* 
 
1 Laboratory of Natural Products and Organic Synthesis, Department of Organic Chemistry,  
Faculty of Science, University of Yaoundé 1, Box: 812, Yaoundé, Cameroon;  
tch_aimee@yahoo.fr (M.A.T.T.); sngouela@yahoo.fr (S.A.N.); tsamoet@yahoo.fr (E.T.) 
2 Antimicrobial & Biocontrol Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants 
Studies, Department of Biochemistry, Faculty of Science, University of Yaoundé I,  
Yaoundé P.O. Box: 812, Yaoundé, Cameroon; ngouanathi@yahoo.com (T.K.N.); 
toghueo.rufin@yahoo.fr (R.M.T.K.) 
3 Chemistry Department, Organic and Bioorganic Chemistry, Bielefeld University,  
P.O. Box 100131, D-33501 Bielefeld, Germany; sebastian.gohlke@uni-bielefeld.de (S.G.); 
norbert.sewald@uni-bielefeld.de (N.S.) 
4 Giresun University, Faculty of Engineering, Department of Industrial Engineering,  
28200 Giresun, Turkey; abdulselam@hotmail.de 
5 Agrı Ibrahim Cecen University, Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences, 
04100 Agri, Turkey; mkuzu@agri.edu.tr 
6 Agrı Ibrahim Cecen University, School of Health, Department of Nutrition and Dietetics,  
04100 Agri, Turkey; veysel_comakli@hotmail.com (V.C.); r.demirdag@hotmail.com (R.D.) 
7 Department of Chemistry, Higher Teacher Training College, University of Yaoundé 1,  
Yaoundé, Cameroon; lentabruno@yahoo.fr 
* Correspondence: fabrice.boyom@fulbrightmail.org 
 
Abstract: The chemical investigation of the anti-yeast methanol extract from the stem bark of 
Terminalia mantaly led to the isolation of seven compounds: 3-O-methyl-4-O-α-
rhamnopyranoside ellagic acid (1), 3-O-mehylellagic acid (2), arjungenin or 2,3,19,23-
tetrahydroxyolean-12-en-28-oïc acid (3), arjunglucoside or 2,3,19,23-tetrahydroxyolean-12-en-
28-oïc acid glucopyranoside (4), 2α,3α,24-trihydroxyolean-11,13(18)-dien-28-oïc acid (5), 
stigmasterol (6), stigmasterol 3-O-β-D-glucopyranoside (7). Their structures were established 
by means of spectroscopic analysis and comparison with published data. Compounds 1-5 were 
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tested in vitro for activity against three pathogenic yeast isolates, Candida albicans, Candida 
parapsilosis and Candida krusei. The activity of compounds 1, 2 and 4 were comparable to that 
of the reference compound fluconazole (MIC values below 32 µg/ml) against the three tested 
yeast isolates. They were also tested for inhibitory properties against four enzymes of metabolic 
significance: Glucose-6-Phosphate Deshydrogenase (G6PD), human erythrocyte Carbonic 
anhydrase I and II (hCA I and hCA II), Glutathione S-transferase (GST). Compound 4 showed 
highly potent inhibitory property against the four tested enzymes with overall IC50 values 
below 4 µM and inhibitory constant (Ki) <3 µM. 
 
Keywords: Anti-yeast; Enzyme inhibitors; Terminalia mantaly; Combretaceae 
 
 
 
1. Introduction 
Fungal diseases affect every year 3-4 million people worldwide. Of particular 
importance, the increasing resistance of pathogenic opportunistic yeasts to current drugs is a 
serious concern and has attracted the attention of the scientific community. New, safe, and cost-
effective drugs of natural or synthetic origin are therefore actively being searched [1]. Recent 
epidemiological data highlight the increasing burden of pathogenic yeasts on people in poor 
settings [2,3,4]. Candida species and Cryptococcus neoformans are the major pathogenic yeasts 
and only few antifungal drugs have been developed so far to treat the invasive infections they 
cause [5,6]. Medicinal plants have shown credibility as sources of treatment for infectious 
diseases [7]. In Cameroon, extracts from medicinal plants such as Terminalia mantaly 
(Combretaceae) are widely used by traditional healers to control diverse infections or 
associated symptoms, including but not limited to dysentery, gastroenteritis, hypertension, 
diabetes, and oral, dental, cutaneous and genital affections [8]. Previous studies on the extracts 
of this plant have indicated antibacterial and antifungal properties, but their chemical 
compositions have not yet been determined. However, phytochemical studies of other species 
of the genus Terminalia have reported the presence of flavonoids, terpenoids and their 
glycosides derivatives, tannins, flavonones and chalcones [9-18]. Besides, in spite of the work 
done on Terminalia species, no investigation has been attempted yet on the enzyme inhibition 
properties of their extracts and constituents targeting Glucose-6-phosphate dehydrogenase, 
Carbonic anhydrase and Glutathione S-transferase. 
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 Glucose-6-phosphate dehydrogenase (G6PD; E.C. 1.1.1.49) enzyme catalyzes the reaction 
of glucose-6-phosphate into phosphogluconate, which is the first step of rate-limiting of 
pentose phosphate pathway. The end products of this pathway are ribose-5-phosphate and 
NADPH. Ribose-5-phosphate is used in DNA or RNA synthesis in cell reproduction, and 
NADPH is used as coenzyme for the enzymes participating in the production of reduced 
glutathione. Given its role in cell growth, this enzyme is of high importance to mammal cells 
[19,20]. However, several studies have shown that this enzyme takes an important role in the 
pathology of some diseases like cancer, hypertension, heart failure and type 2 diabetes. G6PD 
activity increases in cancer cells and its inhibition results in decrease of cell proliferation and 
induction of apoptosis. For example, 6-aminonicotinamide which is an inhibitor of G6PD has 
found use in the therapy of various tumors in the past [21].  
 Carbonic anhydrase (CA; carbonate hydro-lyase, EC 4.2.1.1) enzyme exists commonly 
in living organisms, and has various isoenzymes according to conditions and necessities of the 
medium. It is one of the most studied enzymes and CA-I and CA-II are the most common 
isoenzymes [22]. In many physiological and pathological processes, CAs catalyze the 
conversion of CO2 to HCO3- and H+. In addition, CA inhibitors may be used in the treatment of 
various diseases such as oedema, glaucoma, obesity, cancer, epilepsy and osteoporosis [23].  
 In living cells, the deleterious effects of free radicals and their intermediates are 
eliminated or minimized by various enzymatic and non-enzymatic defense systems. Enzymatic 
defense is provided by several enzymes such as glutathione S-transferase (GST), glutathione 
reductase, glutathione peroxidase, superoxide dismutase, and catalase [24]. The GSTs (EC 
2.5.1.18) are a group of multifunctional enzymes that play an important role in the metabolism 
[25]. GSTs are important for the fight against cancer because of their interactions with 
carcinogens and chemotherapeutic agents. They are the target of antiasthmatic and antitumor 
drugs [26]. Production of excessive amounts of GST in mammalian tumor cells leads to 
resistance to some anticancer drugs and chemical carcinogens [27]. 
 The reduction of drugs effects in tumor cells is an important factor limiting the 
therapeutic efficacy of an antineoplastic agent. The development of this resistance was 
associated with glutathione (GSH) and glutathione S-transferase (GST) levels in cells and 
changes in permeability to the drug. In this regards, G6PD, CA I, II or GST inhibitors may be 
useful because of their several applications, in particular for the treatment of glaucoma, 
epilepsy, cancer and as diuretics. 
 In our search for bioactive secondary metabolites from Cameroonian medicinal plants, 
we have investigated the MeOH extract of the stem bark of Terminalia mantaly L. 
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(Combretaceae) that previously showed anti-yeast activity. We report in this paper the 
inhibitory potential of compounds isolated from this extract against some pathogenic yeasts and 
some enzymes of metabolic significance. 
 
2. Materials and methods.  
2.1. General Experimental Procedures 
Optical rotations were measured on a JASCO digital polarimeter (model DIP-3600). UV 
spectra were determined on a Spectronic Unicam spectrophotometer. IR spectra were 
determined on a JASCO Fourier transform IR-420 spectrometer. 1H and 13C NMR spectra were 
run on a Bruker spectrometer equipped with 5 mm 1H and 13C probes operating at 500 and 125 
MHz, respectively, with TMS as internal standard. Silica gel 230-400 mesh (Merck) and silica 
gel 70-230 mesh (Merck) were used for flash and column chromatography while precoated 
aluminum backed silica gel 60 F254 sheets were used for TLC. Spots were visualized under 
UV light (254 and 365 nm) or using MeOH-H2SO4 reagent. 
 
2.2. Plant Material 
The stem bark of Terminalia mantaly (Combretaceae) was collected in Yaoundé in May 
2012 and identified at the Cameroon National Herbarium where a voucher specimen is 
deposited under the reference N° 64212/HNC (Terminalia mantaly H. Perrier). 
  
2.3. Microbial isolates  
Yeast isolates were generously provided by the Laboratory of Clinical Biology, 
Yaoundé Central Hospital and consisted of clinical isolates of Candida albicans, Candida 
krusei and Candida parapsilosis. These yeasts were maintained at room temperature and 
cultured at 37 °C for 24 hours on Sabouraud Dextrose Agar (Oxoid) slants prior to use. 
2.4. Plant extraction and screening of anti-yeast activity 
The harvested T. mantaly stem bark was dried at room temperature and ground using a 
blender. The powdered stem bark (7 kg) was extracted at r.t. with MeOH (48 h). The extract 
was concentrated under vacuum to afford a dark residue (250 g). Minimal Inhibitory 
Concentration (MIC) of the extract was determined according to the CLSI M27-A3 [6] protocol 
with little modifications. The RPMI 1640 supplemented with 2% glucose was used as culture 
medium. Briefly for the fungal susceptibility tests, 50 µL of serially 2-fold diluted 
concentrations of the crude extract were added in triplicate wells of a 96-wells microtiter plate. 
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Fifty µL of fungal inocula standardized to a final concentration of 0.5-2.5x103 CFU/mL were 
then individually added in each well of the plate. Plant crude extract and the positive control 
(fluconazole) at concentrations of 0.12 to 64 µg/mL were tested in a final volume of 100 µL. 
So-prepared plates were incubated at 37 °C for 48 hours. MIC value was subsequently 
determined through macroscopic observation of plate wells, and was defined as the lowest 
concentration of the inhibitor that allowed no visible growth of the microorganism. 
 
2.5. Isolation of compounds and screening for activity 
A portion of 180 g of the extract was subjected to medium pressure flash 
chromatography over silica gel (Merck, 70 – 230 mesh) using mixtures n-hexane-EtOAc of 
increasing polarity [(70:30) – (0:100)] and EtOAc-MeOH [(95:5) – (50:50)], resulting in the 
collection of 75 fractions of 500 mL each, which were combined on the basis of TLC analysis 
to afforded 4 fractions labeled T1-T4. Fraction T1 (m = 14,4 g) obtained from the mixtures of n-
hexane-EtOAc (100:0 to 70:30) was subjected to silica gel column chromatography eluted with 
n-hexane-EtOAc and yielded oils, stigmasterol (6, 23 mg) and arjungenin (3, 7 mg). From 
fraction T2 (m = 60,3 g), eluted with n-hexane-EtOAc [(50:50) – (25:75)], stigmasterol 3-O-β-
D-glucopyranoside (7, 12 mg), arjungenin (3, 17 mg), 2α,3α,24-trihydroxyolean-11,13(18)-
dien-28-oic acid (5, 5.0 mg) and arjunglucoside (4, 6 mg) were isolated. Column 
chromatography of fraction T3 (m= 55.0 g) on silica gel and eluted with the mixtures of EtOAc-
MeOH [(100:0) – (85:15)], yielded 3-O- methylellagic acid 4׳-O-α-rhamnopyranoside (1, 32 
mg), arjungenin (3, 12.0 mg), arjunglucoside (4, 3,5mg), 2α,3α,24-trihydroxyolean-11,13(18)-
dien-28-oic acid (5, 3.5mg) and a dark mixture that was subjected to column chromatography 
on Sephadex LH-20 with MeOH as isocratic eluent and yielded 3-O-methyl ellagic acid (2, 
12,5 mg). Fraction T4 (m= 81.8 g) obtained with the mixtures of EtOAc-MeOH (85:15 to 
65:35) was a complex mixture and thus were not studied. All the isolated compounds were 
screened as described above for anti-yeast activity, and as described below for enzyme 
inhibition activities.  
 
2.6. Purification of Glucose 6-Phosphate Dehydrogenase and activity determination  
G6PD was purified from the gill tissue of Lake Van fish according to Kuzu et al. [28], 
and the enzyme activity was determined spectrophotometrically using a Shimadzu 
spectrophotometer (UV-1800) at 25 °C, according to the method described by Beutler [29] and 
based on the principle of the reduction of NADP+ to NADPH in the presence of glucose 6-
phosphate and absorbance recorded at 340 nm. 
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2.7. Purification of carbonic anhydrase isoenzymes by affinity chromatography and 
activity determination 
The purification of hCA I and II isozymes was performed with a simple one step 
method by a Sepharose-4B anilinesulfanilamide affinity column chromatography as previously 
described [30]. 
The esterase activity was assessed following the change in absorbance of 4-
nitrophenylacetate (NPA) to 4-nitrophenylate ion at 348 nm over a period of 3 min at 25 ᵒC 
using a spectrophotometer (Beckman Coulter UV-VIS) according to the method described by 
Verpoorte et al. [31].  
 
2.8. Purification of Glutathione -S Transferase enzyme and activity determination 
  
Firstly, heamolysate from human erythrocytes was prepared according to the method of 
Hunaiti et.al. [32]. The prepared heamolysate was directly applied to the glutathione-agarose 
affinity column and washed with 10 mM KH2PO4 and 0.1 M KCl (pH 8.0). The washing 
procedure was monitored on a spectrophotometer through equal-to-blind absorbance values. 
After the column was stabilized, the enzyme was purified by gradient elution at +4°C [24, 33]. 
Elution solvent was prepared from a solvent gradient containing 50 mM Tris–HCl and (1.25– 
10 mM GSH, pH 9.5). Thereafter, 1-chloro-2,4-dinitrobenzene was used to determine GST 
enzyme activity. In fact the product obtained using this substrate, dinitrobenzene S-glutathione 
(DNB-SG) displays maximum absorbance at 340 nm. Activity measurements were thus carried 
out using the absorbance increment at this wavelength. [34]. 
 
2.9. In vitro inhibition and Kinetic studies  
To determine the effects of compounds on enzymes, enzymes activities were measured 
with saturated substrate concentration and five different inhibitor concentrations. The 50% 
inhibitory concentrations (IC50) were determined by plotting curves of % inhibition versus 
compound concentration. Results are reported as IC50 values. Ki constants were calculated 
using the Cheng-Prusoff equation [35]. 
 
3. Results and Discussion 
 The methanol extract of the stem bark of Terminalia mantaly was screened for anti-
yeast activity in vitro against three clinical isolates consisting of Candida albicans, Candida 
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krusei and Candida parapsilosis. The crude extract exhibited good activity with MIC values of 
24 µg/mL against C. parapsilosis and 39 µg/mL against C. albicans and C. krusei (Table 1).  
Table 1: Anti-yeast activity of Terminalia mantaly extract and isolates 
 C. parapsilosis C. albicans C. krusei 
 *MIC (µg/mL± SD) 
MeOH Extract 24.00± 0.21 39.00± 0.33 39.00± 0.30 
Fraction T1 1250.00± 1.23 2500.00± 0.98 2500.00± 1.03 
Fraction T2 39.00± 0.38 >5000 >5000 
Fraction T3 0.16 ± 0.02 0.64 ± 0.12 0.02 ± 0.09 
Fraction T4 >5000 >5000 >5000 
1 
39.00± 0.88 (80.4 
µM) 
9.70± 0.72 (20 µM) >5 (10.30 µM) 
2 
78.00± 0.92 (247.6 
µM) 
156.00± 1.00 (495 
µM) 
19.50± 0.57 (61.9 µM) 
3 >5000(9487 µM) >5000 (9487 µM] >5000 (9487 µM) 
4 
39.00± 0.13 (56.60 
µM)  
9.70± 0.36 (14.07 
µM) 
312.00± 1.04 (452 µM) 
5 >5000 (9823 µM) >5000 (9823 µM) >5000 (9823 µM) 
**Fluconazole 
2.00± 0.01 (6.53 
µM) 
8.00± 0.25 (26.14 
µM) 
32.00± 0.42 (10.45 µM) 
*Plant extracts were tested using the CLSI M27-A3 [6] protocol. Activity was expressed as minimal inhibitory 
concentration at which there were no visible fungal growth; **Reference used as positive control. 
 
The flash chromatography of the crude extract generated 4 fractions exhibiting varying 
antifungal activities. As shown in table 1, fraction T3 was the most active, with  activity 
magnification over 100 times against C. parapsilosis and C. krusei (MIC: 0.16 µg/mL and 0.02 
µg/mL respectively) and over 60 times against C. albicans (0.64 µg/mL). C. krusei was the 
most susceptible isolate to fraction T3. Compounds 1, 2, 3, 4, and 5 that were isolated from 
fractions T1-T3 and were also tested for biological activity (Table 1; Figure 1). Compounds 6 
and 7 were not tested due to reduced solubility in the culture medium. From the results 
achieved, compounds 1 and 4 showed the best potency against C. albicans with MIC of 9.7 
µg/ml. They also moderately inhibited C. parapsilosis with an MIC of 39 µg/ml. Besides, 
compound 2 inhibited C. krusei with an MIC of 19.5 µg/ml.  
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Fig.1. Structures of the isolated compounds 1-7 from Terminalia mantaly (Combretaceae) 
The isolated compounds were tested against pathogenic yeast isolates and enzymes of metabolic significance. 1: IC50= 39 
µg/mL C. parapsilosis; 9.7 µg/mL C. albicans; >5 µg/mL C. krusei; CAI: IC50= 53.31 µM, Ki= 44.11 µM; CAII: IC50= 69.11 
µM, Ki= 55.78 µM; GST: IC50= 63.01 µM, Ki= 42.00 µM. 2: IC50= 78 µg/mL C. parapsilosis; 156 µg/mL C. albicans; 19.5 
µg/mL C. krusei. 3: C. parapsilosis, C. albicans, krusei: IC50> 5000 µg/mL; CAI: IC50= 86.64 µM, Ki= 71.68 µM; GST: IC50= 
1.51 µM, Ki= 1.00 µM. 4: IC50= 39 µg/mL C. parapsilosis; 9.7 µg/mL C. albicans; 312 µg/mL C. krusei; G6PD: IC50= 1.84 
µM, Ki= 0.19 µM; CAI: IC50= 3.28 µM, Ki= 2.72 µM; CAII: IC50= 1.28 µM, Ki= 1.03 µM; GST: IC50= 1.84 µM, Ki= 1.23 
µM. 
 
 
3. NMR spectral data of compounds 1-5 
3-O- methylellagic acid 4׳-O-α-rhamnopyranoside (1) [36] 
Yellowish powder; molecular formula C21H18O12; ESI-MS: [M+Na]+ m/z 485,049 1H NMR 
(300 MHz, DMSO-d6): δH 1.13 (3H, d, CH3, H-61) 3.54 ,(״H, q, J = 8,0 and 12,0 Hz, H-5״), 
4.01 (1H, t, H-43) 4.04 ,(״H, s, OMe-3), 4.72 (1H, brd, J = 8,0 Hz, H-31) 4.94 ,(״H, brd, J = 4,0 
Hz, H-21) 5.47 ,(״H, brs, H-11) 7.52 ,(״H, s, H-5), 7.73 (1H, s, H-513 ;(׳C NMR (125 MHz, 
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DMSO-d6), aglycone moiety: δC 113.4 (C-1), 140.5 (C-2), 141.8 (C-3), 153.1 (C-4), 111.9 (C-
5), 113.4 (C-6), 159.1 (C-7), 114.7 (C-1136.6 ,(׳ (C-2142.2 ,(׳ (C-3146.9 ,(׳ (C-4112.0 ,(׳ (C-5׳), 
107.4 (C-6159.1 ,(׳ (C-7׳); rhamnose moiety: 100.5 (C-170.4 ,(״ (C-270.5 ,(״ (C-372.2 ,(״ (C-
  .(and 61.4 (C-3, OMe (״C-6) 18.3 ,(״C-5) 70.3 ,(״4
 
3-O-methyl ellagic acid (2) [36] 
Yellowish powder; molecular formula C15H8O8; ESI-MS: [M-H]- m/z 315, 
1H NMR (DMSO-d6): δ 7.50 (1H, s,H-5), 7.44 (1H, s, H-5′), 4.02 (3H, s, 3-OMe). 13C NMR 
(DMSO-d6): δ 158.9 (C-7), 158.6 (C-7′), 152.2 (C-4), 148.2 (C-4′), 141.7 (C-2), 140.0 (C-3), 
139.8 (C-3′), 136.1 (C-2′), 112.4(C-1′), 112.1 (C-6), 111.7 (C-1), 111.3 (C-5), 110.1 (C-5′), 
107.2 (C-6′), 60.8 (3-OMe).  
Arjungenin or 2,3,19,23-tetrahydroxyolean-12-en-28-oic acid (3) [37]  
White powder; molecular formula C30H48O6; ESI-MS: [M+Na]+ m/z 527,322. 1H NMR (300 
MHz, DMSO-d6): δH 1.23, 1.09, 0.90, 0.88, 0.84 and 0.65 (each 3H, s); 2.92 (1H, brs, H-18); 
2.86 (1H, d, J = 8 Hz, H-3) and 3.57 (1H, m, H-2); 5.23 (1H, brs, H-12); 13C NMR (125 MHz; 
DMSO-d6): δC 16.8, 17.1, 23.9, 24.9, 28.9 and 24.5; 64.3 (C-23), 80.5 (C-3), 179.6 (C-28), 
122.6 (C-12); 143.9 (C-13).  
 
2,3,19,23-tetrahydroxyolean-12-en-28-oic acid (4) [38] 
White powder; molecular formula C36H58O11; ESI-MS: [M+Na]+ m/z 689,396;  1H NMR (300 
MHz, DMSO-d6): δ 1.23, 1.08, 0.89, 0.86, 0.84 and 0.63 (each 3H, s); between 2.90 and 3.80: 
glucose moiety with anomeric proton at 5,20 (1H, d, J = 6.9 Hz, H-113 ;(׳C NMR (125 MHz; 
DMSO-d6): δ 16.9, 24.5, 24.9 and 28.5; glucose moiety: 61.0, 69.9, 72.8, 77.1, 78.2, 94.5; 64.3 
(C-23), 67.4 (C-2), 80.4 (C-3), 176.3 (C-28), 122.6 (C-12), 143.7 (C-13). 
 
2α,3α,24-trihydroxyolean-11,13 (18)-dien-28-oic acid (5) [39] 
Yellowish powder; molecular formula C30H46O5; ESI-MS: [M+Na]+ m/z 509,375 (calc. 
509,324) for C30H46NaO5); 1H NMR(400 MHz; pyridin-d5): δ 1.58; 1.06; 1.05; 1.03; 0.90 and 
0.87 (each 3H, s); 6.62 (1H, d, J = 8.0 Hz, H-11) and 5.81 (1H, d, J = 8.0 Hz, H-12);  4.38 (1H, 
ddd, J =2.2 ;7.6 and 8.9 Hz, H-2); 3.59 (1H, d, J = 7.5 Hz, H-3); 4.43 (1H, d, J = 8.7 Hz, H-24) 
and 3.75 (1H, d, J = 8,76 Hz, H-24);  2.69 (1H, d, J = 12.4 Hz, H-19) and 2.15 (1H, d, J = 12.4 
Hz, H-19); 13C NMR (125 MHz; pyridin-d5): δC 16.6, 19.5, 19.8, 23.7, 24.0 and 32.1; 65.1 (C-
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24), 68.4 (C-2), 85.5 (C-3), 178,6 (C-28) ;136,1 (C-13); 133,3 (C-18) ; 126,4 (C-12) et 125,9 
(C-11). 
 
Apart from the activity profile described above, MIC values for the other tested fractions 
and compounds were above 39 µg/ml. The activity of compounds 1 and 4 was comparable to 
that of the reference drug fuconazole against C. albicans and, compound 2 showed to be over 
1.5 times more active than the same reference drug against C. krusei. Based on basic skeleton 
of the tested compounds, it is important to notice that one of the most active derivatives, 4 and 
the less active compounds, 3 and 5 are all triterpenoids. Preliminary structure-activity 
relationship (SAR) study clearly indicated that the glycosylation of the acidic function of 
compound 3 at C-28 is important for activity improvement. The other active compounds 1 and 
2 are ellagic acid derivatives. Previous studies have reported the antifungal activity of ellagic 
acid (1a) against fungal strains Trichophyton rubrum, T. verrucosum, T. mentagrophytes, T. 
violaceum, T. schoenleinii, Microsporum canis, C. glabrata, C. albicans and C. tropicalis [40]. 
Also, the observed antifungal potency of compounds 1 and 2, respectively glycosylated and 
methylated derivatives of 1a highlights the potency of this class of secondary metabolites [40]. 
 Overall, it was observed that fraction T3 exerted the more potent effect against the 
tested yeasts, far better than the derived compounds. This is an indication that fractionation has 
declined the anti-yeast activity, emphasizing the relevance of potential synergistic interactions 
among the components of fraction T3. Moreover, these results indicate future directions in the 
progression of this fraction to develop a phytodrug against yeasts infections.  
Selected isolated compounds were further tested against G6PD, Carbonic anhydrase I, II 
and GST enzymes. The results achieved are shown in table 2. 
Table 2: Inhibitory parameters of isolated compounds against G6PD, CAI, CAII, and GST 
 G6PD CAI CAII GST 
 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
aIC50(µM) n.a na na 1.84± 
0.31 
53.31± 
1.09 
 86.64± 
0.93 
3.28± 
0.13 
69.31± 
1.13 
na na 1.03± 
0.01 
63.01± 
1.15 
na 1.51± 
0.78 
1.84± 
0.73 
bKi (µM) n.a na na 0.19± 
0.03 
44.11± 
1,12 
 71.68± 
0.96 
2.72± 
0.64 
55.78± 
0.97 
na na 1.84± 
0.11 
42.00± 
1.39 
na 1.00± 
0.03 
0.19± 
0.77 
                 
Enzymes were expressed and purified, and subsequently assessed for in vitro susceptibility to inhibitors. aSerially 
diluted triplicate concentrations were tested and activity expressed as 50% inhibitory concentration. bInhibitory 
constant which is reflective of the binding affinity; the smaller the Ki, the greater the binding affinity and the 
smaller amount of medication needed in order to inhibit the activity of that enzyme.n.a= non active. 
 The G6PD enzyme was strongly inhibited by the triterpenoid arjunglucoside (4) with 
IC50 value of 1.84 µM and Ki (the inhibitor constant indicating how potent an inhibitor is; or 
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the concentration required to produce half maximum inhibition) value of 0.19 µM. It has been 
shown that this key metabolic enzyme which catalyzes the first step of pentose phosphate 
pathway is expressed abundantly and very active in human tumors [21]. In contrast, G6PD-
deficient tumor cell lines showed relatively slow growth and enhanced apoptosis [41]. Previous 
studies also reported G6PD inhibitory properties for few compounds such as steroids and 
derivatives [42, 43], chalcones [28], catechin gallates [44], and some phenolic molecules [45]. 
In this study, the substituted ellagic acid derived compound 1 did not show any effect on the 
G6PD enzyme activity, although Adem et al [45] reported that ellagic acid inhibited the 
enzyme with an IC50 value of 0.072 mM. The methoxy group in compound 1 may hindrance 
the enzyme-inhibitor interaction. Based on the skeletal features of the tested triterpenoids 3, 4, 
5, the presence of hydroxyl group at C-19 and the glycosylation of C-28 carboxylic group may 
be both factors of activity improvement. The G6PD inhibitory potential of a terpenoid is 
reported here for the first time.  
 Compound 4 exhibited very good potency against both hCAI and hCA II enzymes with 
respective activity parameters of IC50= 3.28 µM and Ki= 2.72 µM; and IC50= 1.28 µM and Ki= 
1.03 µM respectively. The other tested compounds including 3-O-methyl-4-O-α-
rhamnopyranoside ellagic acid (1) and arjungenin (3) were found to be moderately active 
against hCAI and hCA II (compound 1) with IC50 and Ki values globally above 44 µM. 
Previous studies by Sarıkaya et al [46] have indicated that ellagic acid inhibited hCA I and hCA 
II with Ki values of 0.207 and 0.146 mM respectively. In the present study, compound 1, a 
substituted derivative of ellagic acid (1a) has exhibited moderate, however highly improved 
potency toward hCA I (Ki= 44.11 µM) and hCA II (55.78 µM) enzymes. However, this 
substitution has also considerably decreased the activity as observed against the G6PD enzyme. 
In addition to the established role of CA inhibitors (CAIs) as diuretics and antiglaucoma drugs, 
it has recently emerged that they could have potential as novel anti-obesity, anticancer and anti-
infective drugs [47]. The high inhibitory potency of the triterpenoid 4 against CAs indicates 
that it is a promising compound that might be progressed for the formulation of drugs against 
CAIs-related diseases.  
 The screening of 3-O-methyl-4-O-α-rhamnopyranoside ellagic acid (1), arjungenin (3), 
and arjunglucoside (4) against GST enzyme showed inhibitory effects. However, the 
triterpenoids 3 and 4 exhibited highly potent inhibitory effects (IC50s of 1.57 and 1.84 µM 
respectively; and Ki of 1.00 and 1.23 µM respectively). Compound 1 only exerted a moderate 
inhibitory effect on the enzyme (IC50= 63.01 µM; Ki= 42.00 µM). These results are of higher 
significance as GST inhibitors are anti-cancer agents [25, 26]. Ellagic acid (1a) was recently 
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shown to inhibit GSTs A1-1, A2-2, M1-1, M2-2 and P1-1 with IC50 values ranging from 0.04 
to 5 µM [48]. Preliminary SAR studies indicate that the substitution of ellagic acid at C-3 and 
C-4´ gave derivative 1 which showed an IC50 value of 63.01 μM), thus therefore considerably 
decreased the activity. The inhibitory effect of this class of secondary metabolite derivatives is 
reported here for the first time. 
  
Concluding remarks 
The results obtained from the investigation of the methanolic extract of Terminalia 
mantaly stem bark have identified a highly potent anti-yeast fraction T3 that showed to be more 
promising than subsequently isolated compounds. This promising fraction deserves to be 
further investigated with the ultimate aim of formulating a plant-based drug against yeasts 
infections. Compounds 1 and 4 showed anti-yeast activity close to that of the reference drug 
fuconazole against C. albicans. Moreover, compound 2 was over 1.5 times more active than 
fuconazole against C. krusei. Besides, two of the islotated compounds, arjungenin (3) and 
arjunglucoside (4) were found to be very active against enzymes of metabolic significance, 
including G6PD (compound 4) and GST (compounds 3 and 4). Finally, given the anti-yeast 
potency of these compounds, and also the implication of the tested enzymes in some metabolic 
dysfunctions of public health significance (cancer, obesity, epilepsy), we envisage further SAR 
studies to identified potent hit derivatives that should subsequently enter drug development 
pipeline.  
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